KRYS
Price
$184.93
Change
+$1.91 (+1.04%)
Updated
Oct 8, 03:44 PM (EDT)
Capitalization
5.3B
33 days until earnings call
XCUR
Price
$4.88
Change
+$0.57 (+13.23%)
Updated
Oct 8, 12:53 PM (EDT)
Capitalization
27.23M
Interact to see
Advertisement

KRYS vs XCUR

Header iconKRYS vs XCUR Comparison
Open Charts KRYS vs XCURBanner chart's image
Krystal Biotech
Price$184.93
Change+$1.91 (+1.04%)
Volume$700
Capitalization5.3B
Exicure
Price$4.88
Change+$0.57 (+13.23%)
Volume$365
Capitalization27.23M
KRYS vs XCUR Comparison Chart in %
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XCUR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. XCUR commentary
Oct 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a StrongBuy and XCUR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 08, 2025
Stock price -- (KRYS: $183.02 vs. XCUR: $4.31)
Brand notoriety: KRYS and XCUR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 56% vs. XCUR: 46%
Market capitalization -- KRYS: $5.3B vs. XCUR: $27.23M
KRYS [@Biotechnology] is valued at $5.3B. XCUR’s [@Biotechnology] market capitalization is $27.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 1 FA rating(s) are green whileXCUR’s FA Score has 1 green FA rating(s).

  • KRYS’s FA Score: 1 green, 4 red.
  • XCUR’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than XCUR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 7 TA indicator(s) are bullish while XCUR’s TA Score has 5 bullish TA indicator(s).

  • KRYS’s TA Score: 7 bullish, 3 bearish.
  • XCUR’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, KRYS is a better buy in the short-term than XCUR.

Price Growth

KRYS (@Biotechnology) experienced а +3.68% price change this week, while XCUR (@Biotechnology) price change was +5.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.80%. For the same industry, the average monthly price growth was +18.71%, and the average quarterly price growth was +86.69%.

Reported Earning Dates

KRYS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+8.80% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($5.3B) has a higher market cap than XCUR($27.2M). KRYS has higher P/E ratio than XCUR: KRYS (37.20) vs XCUR (0.19). KRYS YTD gains are higher at: 16.826 vs. XCUR (-68.471). KRYS has higher annual earnings (EBITDA): 158M vs. XCUR (-12.42M). KRYS has more cash in the bank: 682M vs. XCUR (7.86M). XCUR has less debt than KRYS: XCUR (476K) vs KRYS (9.68M). KRYS has higher revenues than XCUR: KRYS (359M) vs XCUR (0).
KRYSXCURKRYS / XCUR
Capitalization5.3B27.2M19,474%
EBITDA158M-12.42M-1,272%
Gain YTD16.826-68.471-25%
P/E Ratio37.200.1919,910%
Revenue359M0-
Total Cash682M7.86M8,679%
Total Debt9.68M476K2,034%
FUNDAMENTALS RATINGS
KRYS vs XCUR: Fundamental Ratings
KRYS
XCUR
OUTLOOK RATING
1..100
174
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
32
Undervalued
PROFIT vs RISK RATING
1..100
31100
SMR RATING
1..100
5499
PRICE GROWTH RATING
1..100
4565
P/E GROWTH RATING
1..100
72100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XCUR's Valuation (32) in the null industry is somewhat better than the same rating for KRYS (79) in the Pharmaceuticals Major industry. This means that XCUR’s stock grew somewhat faster than KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (31) in the Pharmaceuticals Major industry is significantly better than the same rating for XCUR (100) in the null industry. This means that KRYS’s stock grew significantly faster than XCUR’s over the last 12 months.

KRYS's SMR Rating (54) in the Pharmaceuticals Major industry is somewhat better than the same rating for XCUR (99) in the null industry. This means that KRYS’s stock grew somewhat faster than XCUR’s over the last 12 months.

KRYS's Price Growth Rating (45) in the Pharmaceuticals Major industry is in the same range as XCUR (65) in the null industry. This means that KRYS’s stock grew similarly to XCUR’s over the last 12 months.

KRYS's P/E Growth Rating (72) in the Pharmaceuticals Major industry is in the same range as XCUR (100) in the null industry. This means that KRYS’s stock grew similarly to XCUR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSXCUR
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 14 days ago
75%
Bearish Trend 13 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XCUR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NYC9.890.01
+0.08%
American Strategic Investment Co
EOG110.45N/A
N/A
EOG Resources
CVRX8.73N/A
N/A
CVRx
UPB18.67-0.30
-1.58%
Upstream Bio Inc
ENPH36.27-0.89
-2.40%
Enphase Energy

XCUR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XCUR has been loosely correlated with XFOR. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if XCUR jumps, then XFOR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XCUR
1D Price
Change %
XCUR100%
+0.94%
XFOR - XCUR
34%
Loosely correlated
+2.08%
ALNY - XCUR
26%
Poorly correlated
+1.68%
NNVC - XCUR
25%
Poorly correlated
-2.07%
PLX - XCUR
25%
Poorly correlated
-3.85%
KRYS - XCUR
24%
Poorly correlated
+1.36%
More